Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington&#039;s disease

Agosta, Federica; Altomare, Daniele; Festari, Cristina; Orini, Stefania; Gandolfo, Federica; Boccardi, Marina; Arbizu, Javier; Bouwman, Femke; Drzezga, Alexander; Nestor, Peter; Nobili, Flavio; Walker, Zuzana; Pagani, Marco

doi:10.1007/s00259-018-4033-0

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease
Authors		Agosta, Federica Altomare, Daniele Festari, Cristina Orini, Stefania Gandolfo, Federica Boccardi, Marina Arbizu, Javier Bouwman, Femke Drzezga, Alexander Nestor, Peter Nobili, Flavio Walker, Zuzana Pagani, Marco show all authors [1 - 13]
Published in		European Journal of Nuclear Medicine and Molecular Imaging. 2018, vol. 45, no. 9, p. 1546-1556
Abstract		To evaluate the incremental value of FDG-PET over clinical tests in: (i) diagnosis of amyotrophic lateral sclerosis (ALS); (ii) picking early signs of neurodegeneration in patients with a genetic risk of Huntington's disease (HD); and detecting metabolic changes related to cognitive impairment in (iii) ALS and (iv) HD patients.
Keywords		Amyotrophic Lateral Sclerosis/diagnostic imaging — Brain — Fluorodeoxyglucose F18 — Humans — Huntington Disease/diagnostic imaging — Positron-Emission Tomography — Radiopharmaceuticals
Identifiers		DOI: 10.1007/s00259-018-4033-0 PMID: 29717332
Full text		Article (Published version) (2.3 MB) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie
Research group		Troubles de mémoire et maladie d'Alzeimer (935)
Citation (ISO format)		AGOSTA, Federica et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. In: European Journal of Nuclear Medicine and Molecular Imaging, 2018, vol. 45, n° 9, p. 1546-1556. doi: 10.1007/s00259-018-4033-0 https://archive-ouverte.unige.ch/unige:114050